Skip navigation
Watchlist Sponsored By :


Current DateTime: 04:58:15 14 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 04:58:15 14 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 04:58:15 14 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Genentech Faces ImClone Pressure on Cancer Drug
By: Reuters | 21 Apr 2008 | 05:15 AM ET
Text Size

Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's [IMCL  Loading...      ()   ] Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.
Genetech
AP

The brokerage said it had learnt from "a reliable public source" that ImClone's [DNA  Loading...      ()   ] medicine had demonstrated an unexpected survival benefit in a second Phase III trial -- the so-called BMS-099 trial for first line metastatic lung cancer.

The revelation came as Genentech announced fresh findings from a clinical trial called Avail showing that Avastin improved progression-free survival in patients with non-small cell lung cancer (NSCLC) but did not prolong their overall survival.

The results mean Erbitux has two Phase III trials with proven survival benefit compared with only one for Avastin, increasing the chances that Erbitux could pose a serious threat to Avastin in the lung cancer treatment market in future.

Avastin, which is vital to the future prospects of both Genentech and its associate Roche Holding, is already approved in NSCLC in the United States and Europe.

Erbitux was initially developed for colon cancer but its sponsors now want to use it in a wider range of tumour types.

It is sold in Europe by Germany's Merck KGaA and in the United States by Bristol-Myers Squibb [BMY  Loading...      ()   ].

Morgan Stanley said the companies had declined to confirm the Erbitux clinical trial news, but shares in Germany's Merck KGaA were likely to rally strongly, ahead of the big ASCO cancer meeting at the end of May.

"An additional 400 million euros revenue for Erbitux in 2012 would translate into a 15 percent increase in our Merck KGaA EPS estimate," the brokerage said.

"We are maintaining our current forecast of 300 million euros in lung in 2012 unchanged until we see the FLEX and BMS-099 data."

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:02:29 14 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters